Biogen’s controversial Alzheimer’s drug generates $2 million sales in first few weeks after approval


Aduhelm by Biogen

Source: Biogen

Biogen‘s Alzheimer’s drug, Aduhelm, generated $2 million in revenue in the first few weeks of its approval, the company said Thursday in releasing its second-quarter earnings along with an open letter about the controversial drug.

Biogen hiked its revenue guidance for the year, saying it expects total sales of $10.65 billion to $10.85 billion this year. That’s up from its previous estimates of $10.45 billion to $10.75 billion. The new forecast assumes “modest” revenue from Aduhelm in 2021, ramping up thereafter, the company said.

Here’s how Biogen did during the three months ended June 30 compared with what Wall Street expected, according to average estimates…

Source cnbc.com

0 0 votes
Article Rating

The eviction ban will expire in 9 days. What to do if you’re at risk

Previous article

California to roll out chip-enabled debit cards to deter theft

Next article

You may also like

Notify of
Inline Feedbacks
View all comments

More in Earnings